News
Over the next 12 years through NHS primary care providers, 1.6 million people are expected to receive tirzepatide, a weight ...
The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared ...
Patients who took a lower dose lost more weight on average. Read more at straitstimes.com. Read more at straitstimes.com.
Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market.
4h
Stocktwits on MSNEli Lilly Hits Dual Wins: Orforglipron, Efsitora Meet Phase 3 Goals For Blood Sugar, Weight Loss And Diabetes CareEli Lilly will likely draw investor focus on Monday as the company said its investigational once-weekly insulin efsitora alfa ...
Pharma companies met with the Trump administration earlier this month to try and defer implementation of the executive order ...
Eli Lilly & Co.’s experimental weight-loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug’s blockbuster potential in the company’s compe ...
How Australian pregnant women are tested for gestational diabetes is set to change, with new national guidelines released ...
CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the ...
CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...
The government issued a serious warning relating to sexual health for Mounjaro users. And tomorrow (23 June), the weight loss ...
One of two newly approved drugs for Alzheimer’s disease has been submitted for National Health Insurance (NHI) coverage, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results